Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Cellnovo Acquires Commercial License for Artificial Pancreas Technology from TypeZero Technologies

2017-04-19 accesswire
PARIS, FRANCE and CHARLOTTESVILLE, VA / ACCESSWIRE / April 18, 2017 / Cellnovo Group ("Cellnovo" EN Paris: CLNV), a medical technology company marketing the first mobile, connected, all-in-one diabetes management system, and digital health company TypeZero Technologies, today announce the completion of a worldwide commercial license agreement for the integration and the commercialization of TypeZero's Artificial Pancreas (AP) technology into Cellnovo's mobile diabetes management system.